These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915 [TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951 [TBL] [Abstract][Full Text] [Related]
5. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320 [TBL] [Abstract][Full Text] [Related]
7. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726 [TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of angiogenesis in operable non-small cell lung cancer. Giatromanolaki A; Koukourakis M; O'Byrne K; Fox S; Whitehouse R; Talbot DC; Harris AL; Gatter KC J Pathol; 1996 May; 179(1):80-8. PubMed ID: 8691350 [TBL] [Abstract][Full Text] [Related]
10. Correlation between survivin expression and prognosis in non-small cell lung cancer. Atikcan S; Unsal E; Demirag F; Köksal D; Yilmaz A Respir Med; 2006 Dec; 100(12):2220-6. PubMed ID: 16650973 [TBL] [Abstract][Full Text] [Related]
11. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714 [TBL] [Abstract][Full Text] [Related]
12. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Skov BG; Fischer BM; Pappot H Lung Cancer; 2008 Jan; 59(1):88-94. PubMed ID: 17905466 [TBL] [Abstract][Full Text] [Related]
13. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146 [TBL] [Abstract][Full Text] [Related]
14. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470 [TBL] [Abstract][Full Text] [Related]
15. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Volm M; Koomägi R Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513 [TBL] [Abstract][Full Text] [Related]
16. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154 [TBL] [Abstract][Full Text] [Related]
17. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029 [TBL] [Abstract][Full Text] [Related]
18. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841 [TBL] [Abstract][Full Text] [Related]